Study of CAR-T Therapy in Older Patients

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Mar 6, 2020

Keywords

ClinConnect Summary

This clinical trial is studying how older patients respond to a special type of treatment called CAR-T cell therapy for certain types of blood cancers, including lymphoma and multiple myeloma. The main goal is to understand how this therapy affects the quality of life for patients aged 60 and older who have not improved with other treatments. Importantly, participants will not receive the CAR-T treatment itself during the study but will continue with their standard cancer care.

To be eligible for this study, participants need to be at least 60 years old and have a confirmed diagnosis of specific types of blood cancers that have not responded to previous treatments. They also need to be able to speak and understand English. However, those with a history of certain mental health conditions or significant brain injuries will not be able to participate. Throughout the trial, participants will share their experiences and insights, helping researchers learn more about how older patients cope with their condition and treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • are ≥60 years old (all cohorts)
• • have pathologically confirmed, relapsed refractory lymphoid malignancy or plasma cell disorder receiving a commercial CAR T-cell product (all cohorts)
• • able to speak and understand English (cohort 1 and 4 only)
• • have a MoCA score of less than 26 out of 30 during the GA visit by a geriatrician prior to CAR T-cell treatment (cohort 4 only)
• Exclusion Criteria:
• • Any prior commercial or investigational CAR T therapy (all cohorts)
• • Current diagnosis of major Axis I psychiatric disorder (DSM-IV), major depression, bipolar disorder, or schizophrenia, as per medical records or patient report (cohort 1 only)
• • History of a neurological disorder, neurodegenerative disease, or traumatic brain injury with loss of consciousness (\>60 minutes), as per medical records or patient report (cohort 1 only)
• • Current ongoing substance abuse and/or history of substance abuse, as per medical records or patient report (cohort 1 only)
• • History of CNS disease (cohort 4 only)